ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2380

Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

Toshihisa Kojima1, Masayo Kojima 2, Hajime Ishikawa 3, Sakae Tanaka 4, Nobuhiko Haga 5, Keiichiro Nishida 6, Masao Yukioka 7, Jun Hashimoto 8, Hisaaki Miyahara 9, Yasuo Niki 10, Tomoatsu Kimura 11, Hiromi Oda 12, Shuji Asai 1, Koji Funahashi 13 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Nagoya City University Graduate School of Medicne, Nagoya, Japan, 3Niigata Rheumatic Center, Niigata, Japan, 4University of Tokyo, Tokyo, Japan, 5The University of Tokyo Hospital, Tokyo, Japan, 6Okayama University, Graduate School of Medicine, Okayama, Japan, 7Yukioka Hospital, Osaka, Japan, 8National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, 9National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, 10Keio University, School of Medicine, Tokyo, Japan, 11University of Toyama, Faculty of Medicine, Toyama, Japan, 12Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 13Kariya-Toyota General Hosptal, Kariya, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Orthopedics, patient-reported outcome measures and depression, rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days, it is very important to evaluate the effectiveness of joint surgery as well as drug therapy based on patient-reported outcome (PRO) The purpose of this study is to explore the relationship among depression, clinical variables and other PROs including physical function.

Methods: Multicenter prospective observational cohort study was conducted among patients who underwent elective joint surgery for RA from April 2012 to March 2016 (Study registration: UMIN000012649). In this study, we collected data at baseline and at 6 or 12 months after the surgery. These data were as follow; age, sex, disease duration, drug therapies, and disease activity (DAS), TUG, and patient-reported outcome [HAQ-DI, EQ-5D (QOL), pain  and BDI-II (depression)]. Correlation between BDI-II and other variables were determined using multiple liner regression analysis.

Results: Totally, 346 patients before elective joint surgery were analyzed cross-sectionally. Mean age, disease duration, pain(VAS), DAS28, HAQ-DI, EQ-5D and BDI-II were 64.2 years, 17.0 years, 36.2 mm, 3.02, 1.11, 0.641 and 13.0, respectively. 52.6% of elective joint surgeries were in upper limbs and 47.4% were in lower limbs.  Multiple liner regression analysis showed that HAQ-DI [B:-0.099 (95%CI:-0.117- -0.08) β:-0.48] pain VAS [B:-0.002 (95%CI:-0.002- -0.001) β:-0.26] and BDI-II [B:-0.003 (95%CI:-0.005- -0.002) β:-0.19] were independent factors for EQ-5D. Furthermore, HAQ-DI [B:3.78 (95%CI:2.54- 5.06) β: 0.33] and pain VAS [B: 0.062 (95%CI: 0.023- 0.101) β 0.17] were significant impact on BDI-II. Especially, walking and eating were independent factors for BDI-II in HAQ-DI categories.

We confirmed these BDI-relating factors above in longitudinal analyses, at last observation (6 or 12 months) after joint surgery in lower limbs (n=138).  BDI-II was remarkably improved from 12.1 (mean) to 10.5.  Change in HAQ-DI had significant impact on that in BDI-II [B:3.183 (95%CI:0.301- 6.065) β:0.229] while that in painVAS did not. The improving in walking was a relevant factor for improving of BDI-II after the surgery [B:2.898(95%CI:0.641- 5.155) β:0.213].

Conclusion: Depression is an important patient-reported outcome for QOL in established RA patients. Improving of physical function with joint surgery in lower limbs caused improving of depression status. Rheumatologists should take the joint surgery into consideration as effective intervention for treatment of established RA patients.


Disclosure: T. Kojima, AbbVie, 2, 8, Abbvie, 8, Astellas, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO., LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Janssen Pharmaceutical, 8, Lilly, 2, 8, Mitsubishi Tanabe, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 8; M. Kojima, None; H. Ishikawa, None; S. Tanaka, Astellas Pharma, Inc., 2, 5, 8, 9; N. Haga, None; K. Nishida, None; M. Yukioka, None; J. Hashimoto, None; H. Miyahara, None; Y. Niki, None; T. Kimura, None; H. Oda, None; S. Asai, AbbVie, 8, Abbvie, 8, Astellas, 8, Bristol-Myers Squibb, 8, Chugai, 8, Chugai Pahrmaceutical, 8, Chugai Pharmaceutical CO.,LTD., 8, Daiichi-Sankyo, 8, Eisai, 8, Janssen, 8, Janssen Pharmaceutical, 8, Pfizer, 8, Takeda, 8, Tanabe Mitsubishi Pharma, 8, UCB Japan, 8; K. Funahashi, None; N. Ishiguro, AbbVie, 2, 8, Abbvie, 2, 8, Asahi Kasei, 2, 8, Astellas, 2, 8, Astellas Pharma, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO.,LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eisai, 2, 8, Eli Lilly, 2, 8, Janssen Pharmaceutical, 8, Kaken, 2, 8, Lilly, 8, Medical Corporation Sanjinkai, 2, 5, 8, Medical Corporation Toukoukai, 2, 5, 8, Mitsubishi Tanabe, 2, 8, Ono, 2, 8, Otsuka, 2, 8, Pfizer, 2, 8, Taisho Toyama, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 2, 8, UCB, 8, Zimmer Biomet, 2, 8.

To cite this abstract in AMA style:

Kojima T, Kojima M, Ishikawa H, Tanaka S, Haga N, Nishida K, Yukioka M, Hashimoto J, Miyahara H, Niki Y, Kimura T, Oda H, Asai S, Funahashi K, Ishiguro N. Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improving-depression-by-joint-surgery-in-established-rheumatoid-arthritis-results-from-multicenter-prospective-cohort-study-for-evaluation-of-joint-surgery-on-patients-reported-outcome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-depression-by-joint-surgery-in-established-rheumatoid-arthritis-results-from-multicenter-prospective-cohort-study-for-evaluation-of-joint-surgery-on-patients-reported-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology